Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKesson
Express Scripts
Medtronic
AstraZeneca

Last Updated: October 2, 2022

CLINICAL TRIALS PROFILE FOR NB-001


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Clinical Trials for NB-001

Trial ID Title Status Sponsor Phase Summary
NCT00453401 ↗ Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis Completed NanoBio Corporation Phase 2 Purpose of this study is to determine the safety and efficacy of topical applications of NB-001 as compared to placebo for the treatment of recurrent herpes labialis.
NCT00683501 ↗ Safety, Efficacy, and Pharmacokinetic Profile of DNB-001 in Subjects With Elevated Intraocular Pressure Completed Danube Pharmaceuticals, Inc. Phase 1/Phase 2 A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase 1I Study to Investigate the Safety, Efficacy, and Pharmacokinetic Profile of Twice-Daily DNB-001 in Previously Untreated Patients with intraocular Hypertension
NCT01321359 ↗ A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis Completed NanoBio Corporation Phase 3 Demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).
NCT01324466 ↗ A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS) Completed NanoBio Corporation Phase 3 The purpose of this study is to demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).
NCT01695187 ↗ NB-001 Treatment of Recurrent Herpes Labialis Unknown status NanoBio Corporation Phase 3 This is a study to test the hypothesis that time to healing of a cold sore will be lower in the active treatment arm of the study when compared to the vehicle (placebo). Subjects with a history of cold sores will be enrolled and administered active treatment or placebo in a blinded manner. Subjects will then be followed to assess time to healing.
NCT05290493 ↗ NB-001 in Children and Adolescents With 22q11 Deletion Syndrome Recruiting Nobias Therapeutics, Inc. Phase 2 This is a Phase 2, randomized, placebo-controlled crossover trial to assess the safety and efficacy of NB-001 in children and adolescents with 22q11DS that manifest commonly associated neuropsychiatric conditions.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for NB-001

Condition Name

Condition Name for
Intervention Trials
Herpes Labialis 2
22q11 Deletion Syndrome 1
Elevated IOP 1
Glaucoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Herpes Labialis 4
Glaucoma 1
Syndrome 1
22q11 Deletion Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for NB-001

Trials by Country

Trials by Country for
Location Trials
United States 68
Canada 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Kentucky 4
Texas 4
South Carolina 4
Pennsylvania 4
Virginia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for NB-001

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 3
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 4
Unknown status 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NB-001

Sponsor Name

Sponsor Name for
Sponsor Trials
NanoBio Corporation 4
Danube Pharmaceuticals, Inc. 1
Nobias Therapeutics, Inc. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Dow
Moodys
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.